Increasing the amount of cytotoxic tumor-infiltrating lymphocytes using vaccination strategies as well as blocking the natural function of the CTLA4 and/or PD-1/PD-L1 immune checkpoints are attractive approaches for anticancer therapies as they enable the host to mount an appropriate immune response to counteract tumor formation, growth and metastasis. Here, PDCD1 is linked to neoplasm.